Inspiris瓣膜植入原生右心室流出道与早期人工瓣膜反流相关
本研究回顾性分析2018至2022年227例接受外科肺动脉瓣置换或管道置换的患者,经倾向性匹配70对后发现,Inspiris组2年免于瓣膜失败率及免于至少中度肺动脉瓣反流率均低于非Inspiris组,而肺动脉瓣狭窄与再干预率无差异;Inspiris植入原生右心室流出道时耐久性更差。
要点
- Inspiris组2年免于瓣膜失败率53.5±9.3% vs 非Inspiris组78.5±5.9%(P=.03)。
- Inspiris组2年免于至少中度肺动脉瓣反流率54.2±9.6% vs 非Inspiris组86.4±4.9%(P<.01)。
- Inspiris植入原生右心室流出道18个月免于瓣膜失败率59.0±9.5% vs 作为管道85.9±9.5%(P=.03)。
核心结论
- Inspiris瓣膜植入原生右心室流出道时早期耐久性差,其独特设计可能与顺应性肺动脉根部不兼容,作者建议可考虑改良植入技术或替代人工瓣膜。
研究设计与样本
- 回顾性研究,纳入2018至2022年接受Inspiris或非Inspiris瓣膜/管道行肺动脉瓣置换或管道置换的患者,共227例,中位年龄19.3岁(四分位距11.8-34.4),Inspiris组120例(52.9%),非Inspiris组107例(47.1%),采用倾向性匹配识别70对患者。
主要发现
- 中位随访26.6个月(四分位距12.4-41.1)。
- 匹配患者中,Inspiris组2年免于瓣膜失败率53.5±9.3% vs 非Inspiris组78.5±5.9%(P=.03),Inspiris组较低。
- 匹配患者中,Inspiris组2年免于至少中度肺动脉瓣反流率54.2±9.6% vs 非Inspiris组86.4±4.9%(P<.01),Inspiris组较低。
- 匹配患者中,2年免于至少中度肺动脉瓣狭窄率两组无差异(P=.61),2年免于再干预率两组无差异(P=.92)。
- Inspiris植入原生右心室流出道时18个月免于瓣膜失败率59.0±9.5% vs 作为管道时85.9±9.5%(P=.03),原生右心室流出道组较低。
临床怎么用
- 作者认为Inspiris瓣膜植入原生右心室流出道时早期耐久性差,可考虑改良植入技术或替代人工瓣膜。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Inspiris Resilia prosthesis (Edwards Lifesciences) has been increasingly used in the pulmonic position with limited performance data. We sought to investigate its durability as a surgical pulmonary valve replacement (PVR). METHODS: We retrospectively reviewed patients who underwent PVR or conduit replacement with an Inspiris or non-Inspiris valve/conduit from 2018 to 2022. The primary end point was freedom from a composite of at least moderate pulmonary regurgitation, pulmonary stenosis, or valve/conduit reintervention. Secondary end points were individual components of the composite outcome. To account for baseline differences, propensity matching identified 70 patient pairs. RESULTS: A total of 227 patients (median age: 19.3 years [interquartile range, 11.8-34.4]) underwent PVR or conduit replacement (Inspiris: n = 120 [52.9%], non-Inspiris: n = 107 [47.1%]). Median follow-up was 26.6 months [interquartile range, 12.4-41.1]. Among matched patients, 2-year freedom from valve failure was lower in the Inspiris group (53.5 ± 9.3% vs 78.5 ± 5.9%, P = .03), as was freedom from at least moderate pulmonary regurgitation (54.2 ± 9.6% vs 86.4 ± 4.9%, P < .01). There was no difference in 2-year freedom from at least moderate pulmonary stenosis (P = .61) or reintervention (P = .92). Inspiris durability was poorer when implanted in the native right ventricular outflow tract compared with as a conduit, with 18-month freedom from valve failure of 59.0 ± 9.5% versus 85.9 ± 9.5% (P = .03). CONCLUSIONS: Early durability of the Inspiris valve is poor when implanted in the native right ventricular outflow tract; its unique design may be incompatible with the compliant pulmonary root. Modified implantation techniques or alternative prostheses should be considered.
引用
- Nguyen SN, Vinogradsky AV, Sevensky R, et al. Use of the Inspiris valve in the native right ventricular outflow tract is associated with early prosthetic regurgitation. J Thorac Cardiovasc Surg. 2023. PMID: 37088131. doi:10.1016/j.jtcvs.2023.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。